Daclizumab safety was evaluated in an integrated analysis of six RRMS trials.
Most AEs were mild or moderate in severity.
A risk for potentially immune-mediated SAEs in liver, skin, and GI organ systems.
AEs occurred throughout treatment with no evidence of accumulated toxicity.
Most AEs resolved spontaneously or with standard medical therapies.